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QUESTIONS
1. Describe the treatment for pemphigus vulgaris.
2. What is mycophenolate mofetil?
3. How did the study protocol affect the outcome of the study?
4. What were the results?
5. What were the conclusions and implications of the study?
The results of well-performed randomized clinical trials 
(RCT) are considered the highest-quality evidence for 
altering or supporting clinical practice. Therapeutic 
options for the treatment of pemphigus vulgaris (PV) 
have evolved over the 50 years since the initial dramatic 
results with corticosteroids. Experts have no consensus 
for the optimal treatment for PV, which is a rare, poten-
tially life-threatening disease (Mimouni and Nousari, 
2003; Martin and Murrell, 2008). Indeed, a recent sys-
tematic review (Martin et al., 2009) discovered insuffi-
cient information for determining the safest and most 
effective treatment regimen. Therefore, an RCT is 
imperative to allow treatments to be thoroughly evalu-
ated. In this issue, Beissert et al. (2010) report the results 
of a 1-year comparison of two doses of mycophenolate 
mofetil (MMF; 2 or 3 g/d) combined with corticoster-
oids and steroids alone in treating PV.
The authors found no difference in the number of patients responding after 1 year between the treatment 
groups but found more side effects in the MMF-treated group, particularly in those treated with 3 g/d. Patients 
treated with MMF, however, were quicker to respond, had a shorter time to sustained response, and exhibited 
a longer time before relapse. MMF also resulted in steroid-sparing effects because the cumulative dose of pred-
nisone was approximately 1 g less in MMF-treated patients. Unfortunately, this latter finding was not associated 
with decreased side effects or decreased morbidity during the study period. The implications of this study remain 
uncertain. Will dermatologists abandon (or at least use lower doses of) MMF, or will the reported secondary out-
comes of faster response and steroid-sparing effects sustain its use? Through the following questions, we examine 
this paper, as well as the subject of PV treatment, in greater detail. For brief answers, please refer to the supple-
mentary information online <http://www.nature.com/jid/journal/v130/n8/suppinfo/jid2010185s1.html>
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